


SCIOS.002C /



PATENT #7/18/02

01.15.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Schreiner, et al.)
App. No. : 10/083,817)
Filed : February 26, 2002)
For : METHODS OF TREATING)
HYPERTENSION AND)
COMPOSITIONS FOR USE)
THEREIN)

Examiner : Unknown

Group Art Unit 1647

RECEIVED

NOV 29 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

A copy of each of the documents cited was filed in the parent application Serial No. 09/392,932, now U.S. Patent No. 6,352,975 which issued March 5, 2002. Accordingly, pursuant to 37 C.F.R. § 1.98(d), copies have not been enclosed. A copy of U.S. Patent No. 6,352,975 is enclosed.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 21 Nov 2002

By: [Signature]


James J. Mullen III, Ph.D.
Registration No. 44,957
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SCIOS.002C1	APPLICATION NO. 10/083,817
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Schreiner, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE February 26, 2002	GROUP 1647

RECEIVED

NOV 29 2002

TECH CENTER 1600/2900



U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS
	1	4,456,550 A	06/1984	Dvorak et al.		
	2	5,194,596 A	03/1993	Tischer et al.		
	3	5,219,739 A	06/1993	Tischer et al.		
	4	5,240,848 A	08/1993	Keck et al.		
	5	5,332,671 A	07/1994	Ferrara et al.		
	6	6,352,975 B1	03/2002	Schreiner et al.		

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	7	0 464 155 B1	05/1997	Europe			
	8	WO 98/20027	05/1998	W.I.P.O.			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	9	Johnson and Schreiner, <i>Kidney Int.</i> 52:1169-1179 (1998).
	10	Johnson et al., <i>Hypertension</i> 19:464-474 (1992).
	11	Roberts and Palade, <i>J. Cell Sci.</i> 108:2369-2379 (1995).
	12	Esser et al., <i>J. Cell. Biol.</i> 140:947-959 (1998).
	13	Kramer et al., <i>Kidney Int.</i> 51:444-447 (1997).
	14	Shulman et al., <i>J. Am. Soc. Nephrol.</i> 7:661-666 (1996).
	15	Ferrara and Davis-Smyth, <i>Endocrine Rev.</i> 18:4-25 (1997)
	16	Monacci et al., <i>Am. J. Physiol.</i> 264:C995-C1002 (1993).
	17	Hariawala et al., <i>J. Surgical Res.</i> 63:77-82 (1996).
	18	Sellke et al., <i>Am. J. Physiol.</i> 271:H713-H720 (1996).
	19	Henry et al., <i>J. Am. Coll. Cardio.</i> 32(2; Suppl. A):65A (1998).
	20	Lombardi et al., <i>Hypertension</i> 33:1013-1019 (1999).
	21	Klagsburn and D'Amore, <i>Cytokine and Growth Factor Reviews</i> 7:259-270 (1996).
	22	Kaplan et al., <i>Pediatr. Nephrol.</i> 4:276 (1990).

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SCIOS.002C1	APPLICATION NO. 10/083,817
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Schreiner, et al.	
		FILING DATE February 26, 2002	GROUP 1647

RECEIVED

NOV 29 2002

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	23 Remuzzi and Ruggenti, <i>Kidney Int.</i> , 48:2-19 (1995).
	24 Neilson and Couser eds., <i>Immunologic Renal Diseases</i> , Lippincott-Raven Philadelphia, 1996, pp. 1161-1181.
	25 Habib et al., <i>Adv. Nephrol.</i> 11:99-128 (1982).
	26 Nangaku et al., <i>Kidney Int.</i> 52:1570-1578 (1997).
	27 Nangaku et al., <i>Kidney Int.</i> 52:182-194 (1997).
	28 Nangaku et al., <i>Curr. Opin. Nephrol. Hypertens.</i> 7:457-462 (1998).
	29 Gerber et al., <i>J. Biol. Chem.</i> 273:3-336-30343 (1998).
	30 Spyridopoulos et al., <i>J. Mol. Cell Cardiol.</i> 29:1321-1330 (1997) [erratum published in <i>J. Mol. Cell Cardiol.</i> 30:897 (1998)].
	31 Gerber et al., <i>Development</i> 126:1149-1159 (1999).
	32 Takeshita et al., <i>J. Clin. Invest.</i> 93:662-670 (1994).
	33 Iruela et al., <i>Am. J. Pathol.</i> 147:1715-1727 (1995).
	34 Kitamura et al., <i>Exp. Nephrol.</i> 6:328-336 (1998).
	35 Tudor et al., <i>J. Clin. Invest.</i> 95:1798-1807 (1995).
	36 Banai et al., <i>Circulation</i> 89:2183-2189 (1994).
	37 Alon et al., <i>Nat. Med</i> 1:1024-1028 (1995).
	38 Benjamin et al., <i>J. Clin. Invest.</i> 103:159-165 (1999).
	39 Papapetropoulos et al., <i>Clin. Invest.</i> 100:3131-3139 (1997).
	40 Wu et al., <i>Am. J. Physiol.</i> 271:H2735-2739 (1996).
	41 Ku et al., <i>Am. J. Physiol.</i> 265:H586-592 (1993).
	42 Gordjani et al., <i>Semin. Thromb. Hemost.</i> 23:281-293 (1997).
	43 Concepcion et al., "Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: Effects of angiotensin converting enzyme inhibition." <i>Journal of Hypertension</i> . 16(6):863-870 (1998).
	44 Abstract. XP-002134130.
	45 Voelkel et al., (1996) "Vascular endothelial growth factor in pulmonary hypertension." <i>Annals of the New York Academy of Sciences</i> . 186-93 (1996).

S:\DOCS\JMJM-9255.DOC
112102

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



PATENT

Case Docket No. SCIOS.002C/.
Date: November 21, 2002

1647
#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Schreiner, et al.
Appl. No. : 10/083,817
Filed : February 26, 2002
For : METHODS OF TREATING
HYPERTENSION AND
COMPOSITIONS FOR USE
THEREIN
Examiner : Unknown
Group Art Unit : 1647

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first class mail in
) an envelope addressed to: United States Patent
) and Trademark Office, P.O. Box 2327,
) Arlington, VA 22202, on

November 21, 2002

(Date)

James J. Mullen III, Ph.D., Reg. No. 44,957

RECEIVED

NOV 29 2002

TRANSMITTAL LETTER

TECH CENTER 1600/2900

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 listing forty-five (45) references; providing one reference.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

James J. Mullen III, Ph.D.
Registration No. 44,957
Attorney of Record
Customer No. 20,995
(619) 235-8550